EVAX (Evaxion Biotech) Bathi resik saben saham sajrone 12 wulan pungkasan

Evaxion Biotech A/S leverages its Inertia AI platform to develop cancer vaccines, generating payments from pharmaceutical behemoths. The TTM annual earnings per share reflects this process, where the parameter value equals -1.05. Digital optimization of development reduces intellectual property costs; however, the lack of stable commercial sales leaves the company's financial position dependent on external grants and subsidies.

EVAX (Evaxion Biotech AS) riwayat Bathi saben saham sajrone rolas wulan pungkasan saka 04.07.2022 nganti 12.11.2026

Rincian analitis lan laporan data perusahaan Evaxion Biotech (EVAX)

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan rega Evaxion Biotech A/S|EVAX - Prakiraan gabungan firma investasi

- indikator valuasi pasar bisnis:

Biji pasar Evaxion Biotech|EVAX - Nilai Dipunlarasaken Utang lan Kas

- indikator nilai aset resik miturut neraca:

Nilai Buku saben Saham Evaxion|EVAX - Nilai Buku Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku evaxion-biotech.com|EVAX - Gunggung Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

Utang marang Ekuitas Evaxion Biotech A/S|EVAX - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Evaxion Biotech Corp|EVAX - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Evaxion Biotech|EVAX - Utang jangka dawa|Utang jangka cendhak perusahaan Evaxion|Rasio cepet evaxion-biotech.com

- indikator pendapatan resik lan kelipatan nilai:

EVAX - Bathi pungkasan|Bathi mangsa ngarep Evaxion Biotech A/S|EVAX - Nilai perusahaan marang bathi resik|Pangali Forward P/E Evaxion|EVAX - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Evaxion Biotech|EVAX - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Evaxion|EVAX - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan evaxion-biotech.com|EVAX - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Evaxion Biotech A/S

Ringkesan analitik perusahaan:Evaxion Biotech A/S (EVAX)

Long-term asset screening requires a priority assessment of a business's ability to generate real income. This metric is calculated as the ratio of total net profit over four quarters to the total number of shares outstanding. For Evaxion Biotech (EVAX), which focuses on high-risk AI vaccines, this indicator reflects the efficiency of innovation monetization. Analyzing the rolling year earnings per share allows for the identification of capital resilience against technological shocks. The trend line determines the probability of a future price correction.

Pesaing utama